SCHEDULE
PART 1 [1]
CONTROLLED DRUGS TO WHICH ARTICLE
12(4) OF THE LAW APPLIES
1 The
following substances and products, namely –
(a) 1,4-butanediol
1-Cyclohexyl-4-(1,2diphenylethyl)piperazine (MT-45)
1-(3,4-Methylenedioxybenzyl)butyl-(ethyl)amine
1-(3,4-Methylenedioxybenzyl)butyl-(methyl)amine
2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine
2-(1,4-Dimethoxy-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine
2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine
2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine
2-(α-Methyl-3,4-methylenedioxyphenethylamino)ethanol
2,4-dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinolin-9-yl}methanone
(LSZ)
2,5-Dimethoxy-α,
4-dimethyl-phenethylamine
2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol
(also known as O-desmethyltramadol)
2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol
2-Amino-1-(3,4-dimethoxyphenyl)ethanol
2-Methoxyethyl(α-methyl-3,4-methylenedioxyphenethyl)amine
3,4-Dichloromethylphenidate
(3,4-DCMP)
3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide
(AH-7921)
4-Bromo-
β,2,5-trimethoxyphenethylamine
4-Bromo-2, 5-dimethoxy-
methyl-phenethylamine
4-Iodo-2,5-dimethoxy-α-methylphenethyl(dimethyl)amine
4-Methyl-aminorex
4-methylmethylphenidate
4-Methyl-5-(4methylphenyl)-4,5-dihydrooxazol-2-amine
(4,4-DMAR)
(6aR,9R)-4-acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
(ALD-52)
(6aR,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
(AL-LAD)
(6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
(ETH-LAD)
(6aR,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
(PRO-LAD)
Allyl(α-methyl-3,4-methylenedioxyphenethyl)amine
Benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine
Bufotenine
Cathinone
Coca leaf
Concentrate of
poppy-straw
Cyclopropylmethyl(α-methyl-3,4-methylenedioxyphenethyl)amine
Dihydroetorphine
Dimethyl(α-methyl-3,4-methylenedioxyphenethyl)amine
Ethylnaphthidate
Ethylphenidate
Eticyclidine
Etryptamine
Gamma-butyrolactone
4-hydroxybutanoic acid
(4-hydroxy-n-butyric acid; gamma-hydroxybutyric acid)
Isopropylphenidate (IPP or IPPD)
Khat
Lysergamide
Lysergide and other N-alkyl
derivatives of lysergamide
Mescaline
Methcathinone
Methylamphetamine
Methylnaphthidate (HDMP-28)
N-adamantyl-1-pentyl-1H-indazole-3-carboxamide
(AKB-48)
N-adamantyl-1(5-fluoropentyl)-1H-indazole-3-carboxamide
(5F-AKB-48)
N-adamantyl-1(5-fluoropentyl)-1H-indole-3-carboxamide
(STS-135)
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
(5F-AB-PINACA)
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
(AB-FUBINACA)
N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxyl-amine
N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxyl-amine
N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxyl-amine
N.N-Diethyltryptamine
N.N-Dimethyltryptamine
N-Hydroxy-tenamphetamine
N-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydro-xylamine
O-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydro-xylamine
Propylphenidate
Psilocin
Quinolin-8-yl-1-(5fluoropentyl)-1H-indole-3-carboxylate
(5F-pB-22)
Quinolin-8-yl-1-(cyclohexylmethyl)-1H-indole-3-carboxylate
(BB-22)
Quinolin-8-yl-1-pentyl-1H-indole-3-carboxylate
(PB-22)
Raw opium
Rolicyclidine
Tenocyclidine
α,
α-Dimethyl-3,4-methylenedioxyphenethyl (methyl)amine
α,
α-Dimethyl-3,4-methylenedioxyphenethylamine
α-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine
α-Methyl-4-(methylthio)phenethylamine
(also known as 4-Methylthioamphetamine)
α-Methylphenethylhydroxylamine
(also known as N-Hydroxyamphetamine)
β
-Methoxy-3,4-methylenedioxyphenethylamine
β,2,5-Trimethoxy-4-methylphenethylamine
β,3,4,5-Tetramethoxyphenethylamine;
(b) any compound (not being a compound for the
time being specified in sub-paragraph (a)) structurally derived from
tryptamine or from a ring-hydroxy tryptamine by modification in any of the
following ways, that is to say –
(i) by substitution
at the nitrogen atom of the sidechain to any extent with alkyl or alkenyl
substituents, or by inclusion of the nitrogen atom of the side chain (and no
other atoms of the side chain) in a cyclic structure,
(ii) by
substitution at the carbon atom adjacent to the nitrogen atom of the side chain
with alkyl or alkenyl substituents,
(iii) by
substitution in the 6-membered ring to any extent with alkyl, alkoxy,
haloalkyl, thioalkyl, alkylenedioxy, or halide substituents,
(iv) by
substitution at the 2-position of the tryptamine ring system with an alkyl
substituent;
(c) any
compound (not being methoxyphenamine or a compound for the time being specified
in sub-paragraph (a) above) structurally derived from phenethylamine, an
N-alkylphenethylamine, a-methylphenethylamine,
an N-alkyl-a-methylphenethylamine, a-ethylphenethylamine, or an N-alkyl-a-ethylphenethylamine by substitution in the ring to any extent with
alkyl, alkoxy, alkylenedioxy or halide substituents, whether or not further
substituted in the ring by one or more other univalent substituents;
(d) any
compound (not being a compound for the time being specified in Part II of this Schedule)
structurally derived from fentanyl by modification in any of the following
ways, that is to say –
(i) by replacement of
the phenyl portion of the phenethyl group by any heteromonocycle whether or not
further substituted in the heterocycle,
(ii) by
substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy,
halogeno, haloalkyl, amino or nitro groups,
(iii) by
substitution in the piperidine ring with alkyl or alkenyl groups,
(iv) by
substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or
haloalkyl groups,
(v) by substitution at the
4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or
acyloxy group,
(vi) by
replacement of the N-propionyl group by another acyl group;
(e) any
compound (not being a compound for the time being specified in Part II of this Schedule)
that is structurally derived from pethidine by modification in any of the
following ways, that is to say –
(i) by replacement of
the 1-methyl group by an acyl alkyl whether or not unsaturated, benzyl or
phenethyl group, whether or not further substituted,
(ii) by
substitution in the piperidine ring with alkyl or alkenyl groups or with a
propano bridge, whether or not further substituted,
(iii) by
substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or
haloalkyl groups,
(iv) by
replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any
alkoxyalkyl or acyloxy group,
(v) by formation of an
N-oxide or of a quaternary base;
(f) any
compound (not being bupropion, cathinone, diethylpropion, pyrovalerone or a
compound for the time being specified in sub-paragraph (a)) structurally
derived from 2-amino-1-phenyl-1-propanone by modification in any of the
following ways, that is to say –
(i) by substitution
in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl
or halide substituents, whether or not further substituted in the phenyl ring
by one or more other univalent substituents,
(ii) by
substitution at the 3-position with an alkyl substituent,
(iii) by
substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion
of the nitrogen atom in a cyclic structure;
(g) any
compound structurally derived from 2-aminopropan-1-one by substitution at the
1-position with any monocyclic, or fused-polycyclic ring system (not being a
phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is
further modified in any of the following ways, that is to say –
(i) by substitution
in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide
substituents, whether or not further substituted in the ring system by one or
more other univalent substituents,
(ii) by
substitution at the 3-position with an alkyl substituent,
(iii) by
substitution at the 2-amino nitrogen atom with alkyl or dialkyl groups, or by
inclusion of the 2-amino nitrogen atom in a cyclic structure;
(ga) any
compound (not being a compound specified in sub-paragraph (a))
structurally derived from 1-benzofuran, 2, 3-dihydro-1-benzofuran, 1H-indole,
indoline, 1H-indene, or indane by substitution in the 6-membered ring with a
2-ethylamino substituent whether or not further substituted in the ring system
to any extent with alkyl, alkoxy, halide or haloalkyl substituents and whether
or not substituted in the ethylamino side -chain with one or more alkyl
substituents;
(gb) any
compound (not being benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine) structurally derived from
mescaline, 4-bromo-2, 5-dimethoxy-α-methylphenethylamine, 2, 5-dimethoxy-α,4-dimethylphenethylamine,
N-hydroxytenamphetamine, or a compound specified in sub-paragraph (a) or
(c), by substitution at the nitrogen atom of the amino group with a benzyl
substituent, whether or not substituted in the phenyl ring of the benzyl group
to any extent;
(h) 1-benzylpiperazine;
(i) any
compound (not being a compound for the time being specified in Part 2 of
this Schedule) structurally derived from 1-benzylpiperazine or 1-phenylpiperazine
by modification in any of the following ways –
(i) by substitution
at the second nitrogen atom of the piperazine ring with alkyl, benzyl,
haloalkyl or phenyl substituents,
(ii) by
substitution in the aromatic ring to any extent with alkyl, alkoxy,
alkylenedioxy, halide or haloalkyl substituents;
(j) the
following substances –
[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1, 2, 3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone
3-Dimethylheptyl-11-hydroxyhexahydrocannabinol
[9-Hydroxy-6-methyl-3-[5-phenylpentan-2-yl] oxy-5, 6, 6a, 7, 8, 9,
10, 10a-octahydrophenanthridin-1-yl] acetate
9-(Hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7, 10,
10a-tetrahydrobenzo[c]chromen-1-ol;
(k) any
compound structurally derived from 3-(1-naphthoyl)indole, 3‑(2-naphthoyl)
indole, 1H-indol-3-yl-(1-naphthyl)methane or 1H‑indol-3-yl-(2-naphthyl)methane
by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl,
alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N‑methylpiperidin-2-yl)methyl
or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole
ring to any extent and whether or not substituted in the naphthyl ring to any
extent;
(l) any
compound structurally derived from 3-(1-naphthoyl)pyrrole or
3-(2-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring
by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl,
cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl,
whether or not further substituted in the pyrrole ring to any extent and
whether or not substituted in the naphthyl ring to any extent;
(m) any
compound structurally derived from 1-(1-naphthylmethylene)indene or
1-(2-naphthylmethylene)indene by substitution at the 3-position of the indene
ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl,
cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl,
whether or not further substituted in the indene ring to any extent and whether
or not substituted in the naphthyl ring to any extent;
(n) any
compound structurally derived from 3-phenylacetylindole by substitution at the
nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl,
hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl
or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole
ring to any extent and whether or not substituted in the phenyl ring to any
extent;
(na) any compound
structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the
5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted
in the cyclohexyl ring to any extent;
(nb) any
compound structurally derived from 3-benzoylindole by substitution at the
nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl,
hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl
or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole
ring to any extent and whether or not substituted in the phenyl ring to any
extent;
(nc) any
compound structurally derived from 3-(1-adamantoyl)indole or
3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring
by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl,
cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl,
whether or not further substituted in the indole ring to any extent and whether
or not substituted in the adamantyl ring to any extent;
(nd) any
compound structurally derived from
3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the
nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl,
hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl
or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole
ring to any extent;
(o) Any
compound (not being pipradrol) structurally derived from piperidine,
pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon
atom with a diphenylmethyl group, whether or not the compound is further
modified in any of the following ways, that is to say –
(i) by substitution
in any of the phenyl rings to any extent with alkyl, alkoxy, haloalkyl or
halide groups,
(ii) by substitution
at the methyl carbon atom with an alkyl, hydroxyalkyl or hydroxy group,
(iii) by substitution at the
ring nitrogen atom with an alkyl, alkenyl, haloalkyl or hydroxyalkyl group;
(p) 1-phenylcyclohexylamine
or any compound (not being eticyclidine, ketamine, phencyclidine,
rolicyclidine, tenocyclidine or tiletamine) structurally derived from 1-phenylcyclohexylamine
or 2-amino-2-phenylcyclohexanone by modification in any of the following ways,
that is to say –
(i) by substitution
at the nitrogen atom to any extent by alkyl, alkenyl or hydroxyalkyl groups, or
replacement of the amino group with a 1-piperidyl, 1-pyrrolidyl or 1-azepyl
group, whether or not the nitrogen containing ring is further substituted by
one or more alkyl groups,
(ii) by
substitution in the phenyl ring to any extent by amino, alkyl, hydroxy, alkoxy
or halide substituents, whether or not further substituted in the phenyl ring
to any extent,
(iii) by
substitution in the cyclohexyl or cyclohexanone ring by one or more alkyl
substituents,
(iv) by
replacement of the phenyl ring with a thienyl ring;
(q) any
compound (not being clonitazene, etonitazene, nabilone, zafirlukast, or a
compound for the time being specified in sub-paragraphs (j) to (nd))
structurally related to 1-pentyl-3-(1-naphthoyl)indole (JWH-018), in that the
four sub-structures, that is to say the indole ring, the pentyl substituent,
the methanone linking group and the naphthyl ring, are linked together in a
similar manner, whether or not any of the sub-structures have been modified,
and whether or not substituted in any of the linked sub-structures with one or
more univalent substituents and where the modifications of the sub-structures are
limited to any the following, that is to say –
(i) replacement of
the indole ring with indane, indene, indazole, pyrrole, pyrazole, imidazole,
benzimidazole, or pyrazolo(3,4-b)pyridine,
(ii) replacement
of the pentyl substituent with alkyl, alkenyl, benzyl, cycloalkylmethyl,
cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, 2-(4-morpholinyl)ethyl, or
(tetrahydropyran-4-yl)methyl,
(iii) replacement
of the methanone linking group with an ethanone, carboxamide, carboxylate,
methylene bridge or methine group,
(iv) replacement
of the 1-naphthyl ring with 2-naphthyl, phenyl, benzyl, adamantyl, cycloalkyl,
cycloalkylmethyl, cycloalkylethyl, bicyclo[2.2.1]heptanyl,
1,2,3,4-tetrahydronaphthyl, quinolinyl, isoquinolinyl, 1
amino-1-oxopropan-2-yl, 1-hydroxy-1-oxopropan-2-yl, or piperazinyl.
2 Any
stereoisomeric form of a substance specified in paragraph 1 above.
3 Any
ester or ether of a substance specified in paragraph 1 (not being
2-((dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol).
3A Any ester or ether of a
substance specified in paragraph 2.
4 Any
salt of a substance specified in any of paragraphs 1 to 3 above.
5 Any
preparation or other product containing a substance or product specified in any
of paragraphs 1 to 4 above.
PART 2[2]
CONTROLLED DRUGS EXCEPTED FROM
PART 1
1 The
compounds referred to in Part 1, paragraph 1(d) of this Schedule
are –
Alfentanil
Carfentanil
Lofentanil
Remifentanil
Sufentanil.
2 The
compounds referred to in Part 1, paragraph 1(e) of this Schedule
are –
Allylprodine
Alphameprodine
Alphaprodine
Anileridine
Betameprodine
Betaprodine
Hydroxypethidine
Properidine
Trimeperidine.
3 The compounds referred to
in Part 1, paragraph 1(i) of this Schedule are –
1-(3-chlorophenyl)piperazine
1-(3-chlorophenyl)-4-(3-chlorophenyl)piperazine.
4
5
6